HK1208474A1 - Antigen binding proteins that bind egfr - Google Patents

Antigen binding proteins that bind egfr Download PDF

Info

Publication number
HK1208474A1
HK1208474A1 HK15109023.5A HK15109023A HK1208474A1 HK 1208474 A1 HK1208474 A1 HK 1208474A1 HK 15109023 A HK15109023 A HK 15109023A HK 1208474 A1 HK1208474 A1 HK 1208474A1
Authority
HK
Hong Kong
Prior art keywords
egfr
antibodies
antigen binding
binding proteins
derivatives
Prior art date
Application number
HK15109023.5A
Other languages
English (en)
Chinese (zh)
Inventor
Heyue Zhou
Randy GASTWIRT
Barbara A. Swanson
John Dixon GRAY
Original Assignee
Sorrento Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics, Inc. filed Critical Sorrento Therapeutics, Inc.
Publication of HK1208474A1 publication Critical patent/HK1208474A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15109023.5A 2012-05-17 2013-05-13 Antigen binding proteins that bind egfr HK1208474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648391P 2012-05-17 2012-05-17
US61/648,391 2012-05-17
PCT/US2013/040827 WO2013173255A2 (en) 2012-05-17 2013-05-13 Antigen binding proteins that bind egfr

Publications (1)

Publication Number Publication Date
HK1208474A1 true HK1208474A1 (en) 2016-03-04

Family

ID=49581478

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109023.5A HK1208474A1 (en) 2012-05-17 2013-05-13 Antigen binding proteins that bind egfr

Country Status (7)

Country Link
US (1) US9944707B2 (https=)
EP (1) EP2850105A4 (https=)
JP (1) JP6441792B2 (https=)
CN (1) CN104918956A (https=)
CA (1) CA2872018A1 (https=)
HK (1) HK1208474A1 (https=)
WO (1) WO2013173255A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
EP3280442A4 (en) 2015-04-08 2018-10-31 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd123
KR20180086502A (ko) * 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
TWI736575B (zh) 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
SI3449939T1 (sl) * 2016-04-27 2022-06-30 Green Cross Corporation Farmacevtski sestavek za zaviranje metastaz pri raku, ki kot učinkovino obsega protitelo, ki se specifično veže na receptor za epidermalni rastni faktor
IL263272B2 (en) 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
WO2020247290A1 (en) * 2019-06-04 2020-12-10 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
US20230001008A1 (en) * 2019-08-20 2023-01-05 Kumquat Biosciences Inc. Compositions and methods for targeting cellular molecules
EP4347643A4 (en) * 2021-05-27 2025-09-17 Us Gov Veterans Affairs HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO STREPTOLYSIN O AND METHODS OF USE
CN119053621A (zh) * 2022-02-04 2024-11-29 维硕公司 结合b7-h3的抗原结合蛋白

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
CN101233155B (zh) * 2004-03-19 2013-06-19 英克隆有限责任公司 人抗表皮生长因子受体抗体
EP2332990A1 (en) 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
AU2006211037B2 (en) * 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2007058823A2 (en) 2005-11-12 2007-05-24 Eli Lilly And Company Anti-egfr antibodies
US20090017050A1 (en) 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
AU2009296297A1 (en) 2008-09-26 2010-04-01 Roche Glycart Ag Bispecific anti-EGFR/anti-IGF-1R antibodies
JPWO2010087425A1 (ja) 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
CA2754646A1 (en) 2009-03-31 2010-10-07 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
TW201122101A (en) 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
JP5818003B2 (ja) 2009-11-18 2015-11-18 国立大学法人東北大学 ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
CN103298489A (zh) * 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用

Also Published As

Publication number Publication date
JP6441792B2 (ja) 2018-12-19
EP2850105A2 (en) 2015-03-25
WO2013173255A2 (en) 2013-11-21
CA2872018A1 (en) 2013-11-21
US9944707B2 (en) 2018-04-17
CN104918956A (zh) 2015-09-16
JP2015518827A (ja) 2015-07-06
US20130309233A1 (en) 2013-11-21
EP2850105A4 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
HK1208474A1 (en) Antigen binding proteins that bind egfr
HK1204557A1 (en) Antigen binding proteins that bind pd-l1
HK1221964A1 (zh) 与pd-1结合的抗原结合蛋白
HK1208236A1 (en) Antigen binding proteins that bind ccr2
HK1208181A1 (en) Antigen binding proteins that bind c-met
WO2013173761A3 (en) St2 antigen binding proteins
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
HK1214283A1 (zh) 與erbb3結合的抗原結合蛋白
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
WO2011002968A3 (en) Polypeptides and method of treatment
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
WO2013188448A3 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2014194274A3 (en) Oncostatin m receptor antigen binding proteins
WO2014062245A3 (en) Antigen binding proteins that bind dll-4
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
HK1206610A1 (en) Fully human antibodies that bind to vegfr2
HK1208179A1 (en) Antigen binding proteins that bind igf1r
HK1214167A1 (zh) 與aip2結合的抗感染結合蛋白